Eprex (epoetin alfa) is used to treat anemia caused by reduced endogenous erythropoietin production, primarily in end-stage renal disease and to correct hemostatic defects in uremia. It works by stimulating erythropoietin production. Close monitoring of renal function, bloodwork, iron levels, blood pressure, and symptoms is required due to potential side effects like hypertension, seizures, and bone pain. The dose is adjusted based on hemoglobin levels to maintain appropriate red blood cell counts.
Eprex (epoetin alfa) is used to treat anemia caused by reduced endogenous erythropoietin production, primarily in end-stage renal disease and to correct hemostatic defects in uremia. It works by stimulating erythropoietin production. Close monitoring of renal function, bloodwork, iron levels, blood pressure, and symptoms is required due to potential side effects like hypertension, seizures, and bone pain. The dose is adjusted based on hemoglobin levels to maintain appropriate red blood cell counts.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Eprex (epoetin alfa) is used to treat anemia caused by reduced endogenous erythropoietin production, primarily in end-stage renal disease and to correct hemostatic defects in uremia. It works by stimulating erythropoietin production. Close monitoring of renal function, bloodwork, iron levels, blood pressure, and symptoms is required due to potential side effects like hypertension, seizures, and bone pain. The dose is adjusted based on hemoglobin levels to maintain appropriate red blood cell counts.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Brand Name Generic Indication and Nursing Consideration Action of the Dose and Side Effects
Name Contraindication Drug Administration
Eprex Epoetin alfa Anemia caused by -Monitor renal studies, urinalysis, Erythropoietin is SC/ IV 50- 100 CNS: Seizures, reduction endogenous protein, blood,BUN, creatinine, one factor U/kg 3x/wk, coldness, erythropoietin I&O; report drop in output < 50 controlling rate then adjust dose sweating production primarily ml/hr of red cell by 25 end stage renal disease; production; drug U/kg/dose to CV: to correct hemostatic -monitor blood studies; reticulocyte is developed by maintain Hypertension, defect in uremia. count weekly; check for symptoms recombinant appropriate Hct. hypertensive of anemia, fatigue, pallor, dyspnea DNA encephalopathy Contraindications: technology. Available hypersensitivity to -Assess CNS symptoms; coldness, forms: 2000, MS: bone pain albumin, hypertension, sweating 3000, 4000, erythropoietin levels of 10,000 U/ml >200 mU/ml -Assess CV status: BP before and during Tx; Htn may occur rapidly Precautions: leading to Htn encephalopathy pregnancy class C -Assess patient during hemodialysis for bruits, thrills of shunts; drug prevents severe anemia in chronic renal failure; clotting may need to be treated with increased anticoagulant.
-Monitor serum iron levels, ferritin,
transferring levels; iron therapy may be needed to prevent recurring anemia.
-Monitor blood studies; BUN, WBC,
phosphorus, potassium, bleeding time. Hct should be checked in chronic renal failure.